Roscovitine in cancer and other diseases

Annals of Translational Medicine

Volumn 3, Issue 10, 2015, Pages

  Cicenas, Jonas ^a,b,c   Kalyan, Karthik ^b,d   Sorokinas, Aleksandras ^b   Stankunas, Edvinas ^b,c   Levy, Josh ^b,e   Meskinyte, Ingrida ^f   Stankevicius, Vaidotas ^b,c,g   Kaupinis, Algirdas ^c   Valius, Mindaugas ^c  

^a SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^b Bioinformatics   (Switzerland)

^c VILNIUS UNIVERSITY   (Lithuania)

^d Haffkine Institute for Training Research and Testing India   (India)

^e RTI INTERNATIONAL   (United States)

^f Lithuanian Centre of Non Formal Youth Education   (Lithuania)

^g National Research Institute   (Lithuania)

Author keywords

Cancer; Cyclin dependent kinases (CDK); Kidney diseases; Neurodegeneration; Roscovitine; Small molecule inhibitor

Indexed keywords

EID: 85015487201     PISSN: 23055839     EISSN: 23055847     Source Type: Journal    
DOI: 10.3978/j.issn.2305-5839.2015.03.61     Document Type: Review

References (84)

1. Hunter T, Cooper JA. Protein-tyrosine kinases. Annu Rev Biochem 1985; 54:897-930.
2. Cicenas J, Kueng W, Wight E, et al. Prognostic value of phosphorylated Akt in primary breast cancer. [abstract]. In: Proceedings of the 95th annual meeting of the American Association for Cancer Research (AACR). Orlando: 2004.
3. Cicenas J, Urban P, Vuaroqueaux V, et al. Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2. Breast Cancer Res 2005;7:R394-401.
4. Cicenas J. The potential role of Akt phosphorylation in human cancers. Int J Biol Markers 2008;23:1-9.
5. Cicenas J. The potential role of EGFR/ErbB2 heterodimer in breast cancer. Expert opinion Ther Patents 2007;17:607-16.
6. Kanematsu T, Yano S, Uehara H, et al. Phosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients. Oncol Res 2003;13:289-98.
7. Cicenas J, Urban P, Küng W, et al. Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients. Eur J Cancer 2006;42:636-45.
8. Eppenberger-Castori S, KuengW, Benz C, et al. Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay. J Clin Oncol 2001;19:645-56.
9. DiGiovanna MP, Stern DF, Edgerton SM, et al. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 2005;23:1152-60.
10. Cicenas J, Küng W, Eppenberger U, et al. Increased level of phosphorylated ShcA measured by chemiluminescence-linked immunoassay is a predictor of good prognosis in primary breast cancer expressing low levels of estrogen receptor. Cancers 2010;2:153-64.
11. Derenzini M, Montanaro L, Vici M, et al. Relationship between the RB1 mRNA level and the expression of phosphorylated RB protein in human breast cancers: their relevance in cell proliferation activity and patient clinical outcome. Histol Histopathol 2007;22:505-13.
12. Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci 2005;30:630-41.
13. Welburn JP, Endicott JA. Inhibition of the cell cycle with chemical inhibitors: a targeted approach. Semin Cell Dev Biol 2005;16:369-81.
14. Cicenas J, Valius M. The CDK inhibitors in cancer research and therapy. J Cancer Res Clin Oncol 2011;137:1409-18.
15. Cicenas J, Kalyan K, Sorokinas A, et al. Highlights of the Latest Advances in Research on CDK Inhibitors. Cancers 2014;6:2224-42.
16. Bruyère C, Meijer L. Targeting cyclin-dependent kinases in anti-neoplastic therapy. Curr Opin Cell Biol 2013;25:772-9.
17. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009;8:547-66.
18. Dickson MA. Molecular pathways: CDK4 inhibitors for cancer therapy. Clin Cancer Res 2014;20:3379-83.
19. Azevedo WF, Leclerc S, Meijer L, et al. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem 1997;243:518-26.
20. Meijer L, Borgne A, Mulner O, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997;243:527-36.
21. Schang LM, Bantly A, Knockaert M, et al. Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins. J Virol 2002:76:7874-82.
22. Bain J, McLauchlan H, Elliott M, at al. The specificities of protein kinase inhibitors: an update. Biochem J 2003;371:199-204.
23. Bach S, Knockaert M, Lozach O, et al. Roscovitine targets: protein kinases and pyridoxal kinase. J Biol Chem 2005;280:31208-19.
24. Mapelli M, Massimiliano L, Crovace C, et al. Mechanism of CDK5/p25 binding by CDK inhibitors. J Med Chem 2005;48:671-9.
25. Tang L, Li MH, Cao P, et al. Crystal structure of pyridoxal kinase in complex with roscovitine and derivatives. J Biol Chem 2005;280:31220-9.
26. Raynaud FI, Whittaker SR, Fischer PM, et al. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin Cancer Res 2005;11:4875-87.
27. Whittaker SR, Walton MI, Garrett MD, et al. The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway. Cancer Res 2004;64:262-72.
28. Dey A, Wong ET, Cheok CF, et al. R-Roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis: implications in cancer therapy. Cell Death Differ 2008;15:263-73.
29. Paprskárová M, Krystof V, Jorda R, et al. Functional p53 in cells contributes to the anticancer effect of the cyclin-dependent kinase inhibitor roscovitine. J Cell Biochem 2009;107:428-37.
30. Wesierska-Gadek J, Gritsch D, Zulehner N, et al. Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-a in human ER-positive breast cancer cells. J Cell Biochem 2011;112:761-72.
31. Mohapatra S, Chu B, Wei S, et al. Roscovitine inhibits STAT5 activity and induces apoptosis in the human leukemia virus type 1-transformed cell line MT-2. Cancer Res 2003;63:8523-30.
32. McClue SJ, Blake D, Clarke R, et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 2002;102:463-8.
33. Coker-Gurkan A, Arisan ED, Obakan P, et al. Roscovitine-treated HeLa cells finalize autophagy later than apoptosis by downregulating Bcl-2. Mol Med Rep 2015;11:1968-74.
34. Leitch AE, Riley NA, Sheldrake TA, et al. The cyclin-dependent kinase inhibitor R-roscovitine down-regulates Mcl-1 to override pro-inflammatory signalling and drive neutrophil apoptosis. Eur J Immunol 2010;40:1127-38.
35. Kim EH, Kim SU, Shin DY, et al. Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. Oncogene 2004;23:446-56.
36. Wesierska-Gadek J, Wandl S, Kramer MP, et al. Roscovitine up-regulates p53 protein and induces apoptosis in human HeLaS(3) cervix carcinoma cells. J Cell Biochem 2008;105:1161-71.
37. Wesierska-Gadek J, Gueorguieva M, Horky M. Roscovitine-induced up-regulation of p53AIP1 protein precedes the onset of apoptosis in human MCF-7 breast cancer cells. Mol Cancer Ther 2005;4:113-24.
38. Mihara M, Shintani S, Kiyota A, et al. Cyclin-dependent kinase inhibitor (roscovitine) suppresses growth and induces apoptosis by regulating Bcl-x in head and neck squamous cell carcinoma cells. Int J Oncol 2002;21:95-101.
39. Garrofé-Ochoa X, Cosialls AM, Ribas J, et al. Transcriptional modulation of apoptosis regulators by roscovitine and related compounds. Apoptosis 2011;16:660-70.
40. Lambert LA, Qiao N, Hunt KK, et al. Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. Cancer Res 2008;68:7966-74.
41. Abaza MS, Bahman AM, Al-Attiyah RJ. Roscovitine synergizes with conventional chemo-therapeutic drugs to induce efficient apoptosis of human colorectal cancer cells. World J Gastroenterol 2008;14:5162-75.
42. Weingrill E, Wölfler A, Strunk D, et al. Roscovitine in B-chronic lymphocytic leukemia cells: high apoptosis-inducing efficacy and synergism with alemtuzumab independent of the patients' pretreatment status Haematologica 2007;92:1286-8.
43. Coley HM, Shotton CF, Thomas H. Seliciclib (CYC202; r-roscovitine) in combination with cytotoxic agents in human uterine sarcoma cell lines. Anticancer Res 2007;27:273-8.
44. Fleming IN, Hogben M, Frame S, et al. Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents. Clin Cancer Res 2008;14:4326-35.
45. Coley HM, Shotton CF, Kokkinos MI, et al. The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines. Gynecol Oncol 2007;105:462-9.
46. Maggiorella L, Deutsch E, Frascogna V, et al. Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo. Cancer Res 2003;63:2513-7.
47. Abal M, Bras-Goncalves R, Judde JG, et al. Enhanced sensitivity to irinotecan by Cdk1 inhibition in the p53-deficient HT29 human colon cancer cell line. Oncogene 2004;23:1737-44.
48. Maude SL, Enders GH. Cdk inhibition in human cells compromises chk1 function and activates a DNA damage response. Cancer Res 2005;65:780-6.
49. Gritsch D, Maurer M, Zulehner N, et al. Tamoxifen enhances the anti-proliferative effect of roscovitine, a selective cyclin-dependent kinase inhibitor, on human ER-positive human breast cancer cells. J Exp Ther Oncol 2011;9:37-45.
50. Raynaud FI, Whittaker SR, Fischer PM, et al. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin Cancer Res 2005;11:4875-87.
51. Tirado OM, Mateo-Lozano S, Notario V. Roscovitine is an effective inducer of apoptosis of Ewing's sarcoma family tumor cells in vitro and in vivo. Cancer Res 2005;65:9320-7.
52. Payton M, Chung G, Yakowec P, et al. Discovery and evaluation of dual CDK1 and CDK2 inhibitors. Cancer Res 2006;66:4299-308.
53. Iurisci I, Filipski E, Reinhardt J, et al. Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor. Cancer Res 2006;66:10720-8.
54. Appleyard MV, O'Neill MA, Murray KE, et al. Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model. Int J Cancer 2009;124:465-72.
55. Molinsky J, Klanova M, Koc M, et al. Roscovitine sensitizes leukemia and lymphoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Leuk Lymphoma 2013;54:372-80.
56. Nair BC, Vallabhaneni S, Tekmal RR, et al. Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells. Breast Cancer Res 2011;13:R80.
57. Yakisich JS, Vita MF, Siden A, et al. Strong inhibition of replicative DNA synthesis in the developing rat cerebral cortex and glioma cells by roscovitine. Invest New Drugs 2010;28:299-305.
58. Le Tourneau C, Faivre S, Laurence V, et al. Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. Eur J Cancer 2010;46:3243-50.
59. Benson C, White J, De Bono J, et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 2007;96:29-37.
60. Fischer PM, Gianella-Borradori A. Recent progress in the discovery and development of cyclin-dependent kinase inhibitors. Expert Opin Investig Drugs 2005;14:457-77.
61. Kasai H, Imamura T, Tsuruma K, et al. Effects of roscovitine, a cell cyclin [correction of cycling]-dependent kinase inhibitor, on intraocular pressure of rabbit and retinal ganglion cell damage. Neurosci Lett 2013;535:95-9.
62. Pippin JW, Qu Q, Meijer L, et al. Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist. J Clin Invest 1997;100:2512-20.
63. Chiara M, Menegatti E, Di Simone D, et al. Mycophenolate mofetil and roscovitine decrease cyclin expression and increase p27(kip1) expression in anti Thy1 mesangial proliferative nephritis. Clin Exp Immunol 2005;139:225-35.
64. Li L, Wang H, Kim Js, et al. The cyclin dependent kinase inhibitor (R)-roscovitine prevents alloreactive T cell clonal expansion and protects against acute GvHD. Cell Cycle 2009;8:1794-802.
65. Avunduk AM, Varnell ED, Kaufman HE. The effect of roscovitine on herpetic keratitis. Exp Eye Res 2003;76:679-83.
66. Milovanceva-Popovska M, Kunter U, Ostendorf T, et al. R-roscovitine (CYC202) alleviates renal cell proliferation in nephritis without aggravating podocyte injury. Kidney Int 2005;67:1362-70.
67. Hoogendijk AJ, Roelofs JJ, Duitman J, et al. R-roscovitine reduces lung inflammation induced by lipoteichoic acid and Streptococcus pneumoniae. Mol Med 2012;18:1086-95.
68. Aydemir A, Abbasoglu O, Topaloglu S, et al. Protective effect of roscovitine on renal ischemia-reperfusion injury. Transplant Proc 2002;34:2027-8.
69. http://meetinglibrary.asco.org/content/33727-65
70. Patrick C, Crews L, Desplats P, et al. Increased CDK5 expression in HIV encephalitis contributes to neurodegeneration via tau phosphorylation and is reversed with Roscovitine. Am J Pathol 2011;178:1646-61.
71. Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer. Available online: http://clinicaltrials.gov/show/NCT00372073
72. Zhang R, Liu Y, Zhang J, et al. Intrathecal administration of roscovitine attenuates cancer pain and inhibits the expression of NMDA receptor 2B subunit mRNA. Pharmacol Biochem Behav 2012;102:139-45.
73. Yang L, Gu X, Zhang W, et al. Cdk5 inhibitor roscovitine alleviates neuropathic pain in the dorsal root ganglia by downregulating N-methyl-D-aspartate receptor subunit 2A. Neurol Sci 2014;35:1365-71.
74. Liu X, Liu Y, Zhang J, et al. Intrathecal administration of roscovitine prevents remifentanil-induced postoperative hyperalgesia and decreases the phosphorylation of N-methyl-D-aspartate receptor and metabotropic glutamate receptor 5 in spinal cord. Brain Res Bull 2014;106:9-16.
75. Bukanov NO, Smith LA, Klinger KW, et al. Long-lasting arrest of murine polycystic kidney disease with CDK inhibitorroscovitine. Nature 2006;444:949-52.
76. Bukanov NO, Moreno SE, Natoli TA, et al. CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD. Cell Cycle 2012;11:4040-6.
77. Zencak D, Schouwey K, Chen D, et al. Retinal degeneration depends on Bmi1 function and reactivation of cell cycle proteins. Proc Natl Acad Sci U S A 2013;110:E593-601.
78. Martin KL, Hill GA, Klein RR, et al. Prevention of radiation-induced salivary gland dysfunction utilizing a CDK inhibitor in a mouse model. PLoS One 2012;7:e51363.
79. Zoja C, Casiraghi F, Conti S, et al. Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus. Arthritis Rheum 2007;56:1629-37.
80. Kabadi SV, Stoica BA, Hanscom M, et al. CR8, a selective and potent CDK inhibitor, provides neuroprotection in experimental traumatic brain injury. Neurotherapeutics 2012;9:405-21.
81. Oumata N, Bettayeb K, Ferandin Y, at al. Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1. J Med Chem 2008;51:5229-42.
82. Bettayeb K, Sallam H, Ferandin Y, et al. N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine. Mol Cancer Ther 2008;7:2713-24.
83. Sroka IM, Heiss EH, Havlicek L, et al. A novel roscovitine derivative potently induces G1-phase arrest in platelet-derived growth factor-BB-activated vascular smooth muscle cells. Mol Pharmacol 2010;77:255-61.
84. Houzé S, Hoang NT, Lozach O, et al. Several human cyclin-dependent kinase inhibitors, structurally related to roscovitine, as new anti-malarial agents. Molecules 2014;19:15237-57.